Equities

Santhera Pharmaceuticals Holding AG

Santhera Pharmaceuticals Holding AG

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CHF)1.62
  • Today's Change0.094 / 6.14%
  • Shares traded754.94k
  • 1 Year change-39.85%
  • Beta2.7669
Data delayed at least 15 minutes, as of Jan 17 2022 16:30 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Santhera Pharmaceuticals Holding AG (Santhera) is a Switzerland-based company engaged in the pharmaceutical sector. The Company is involved in the research, development and commercialization of pharmaceutical products for the treatment of neuromuscular and mitochondrial diseases. The Company’s products include Catena and Raxone brands, which are primarily implemented in the symptomatic treatment of Leber's Hereditary Optic Neuropathy (LHON) diseases. Sathera Pharmaceuticals Holding AG operates through its wholly owned subsidiaries: Santhera Pharmaceuticals (Schweiz) AG, Liestal, Santhera Pharmaceuticals (USA) Inc, Santhera Pharmaceuticals (Canada) Inc, Santhera Pharmaceutical (Deutschland) GmbH and Oy Santhera Pharmaceuticals (Finland) Ltd.

  • Revenue in CHF (TTM)11.73m
  • Net income in CHF-56.35m
  • Incorporated2002
  • Employees86.00
  • Location
    Santhera Pharmaceuticals Holding AGHohenrainstrasse 24PRATTELN 4133SwitzerlandCHE
  • Phone+41 619068950
  • Fax+41 619068951
  • Websitehttps://www.santhera.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Newron Pharmaceuticals SpA5.65m-20.40m26.77m23.00--2.95--4.73-1.14-1.140.31680.50810.1109--3.54245,819.10-40.03-25.78-43.68-28.4797.2178.74-360.85-223.51---6.150.7563---25.2918.24-3.91---11.37--
Addex Therapeutics Ltd4.64m-13.05m46.81m23.00--2.43--10.08-0.4017-0.40170.14490.39070.2463--14.11201,902.60-69.23-39.02-81.03-45.52-----281.08-249.48----0.0376--36.8958.1613.00------
Wockhardt Bio AG301.58m-40.88m52.47m----0.1847--0.174-0.7325-0.73255.815.470.47921.802.50---6.50-1.96-8.19-3.0051.4451.88-13.55-4.233.90-3.450.5092---15.93-8.7151.896.81-17.47--
IGEA Pharma NV29.51k-798.68k64.94m--------2,200.49-0.032-0.0320.0012-0.00520.043919.220.2701---119.94-82.99-522.70-117.39-703.70-1,067.77-2,729.63-5,422.790.2301--2.88--5,557.14--40.72------
Spexis AG14.27m-40.80m83.13m--------5.82-3.63-3.631.27-0.52780.341--126.26---97.49---159.15-------285.89-----24.297.31--142,106.90--30.50------
Santhera Pharmaceuticals Holding AG11.73m-56.35m83.55m86.00--5.50--7.13-3.28-3.280.62660.27840.13012.822.15136,337.20-62.51-43.07-106.66-51.3411.7482.58-480.61-138.870.2511-3.890.8385---80.0928.28-256.61---41.93--
RELIEF THERAPEUTICS Holding SA0.00-30.76m347.49m24.00--2.15-----0.0104-0.01040.000.03670.00-------28.70-22.60-32.74-24.44-------6,111.211.78-69.180.0693-------4.93------
Data as of Jan 17 2022. Currency figures normalised to Santhera Pharmaceuticals Holding AG's reporting currency: Swiss Franc CHF

Institutional shareholders

2.83%Per cent of shares held by top holders
HolderShares% Held
Armistice Capital LLCas of 27 Sep 2021494.15k0.91%
Credit Suisse Asset Management (Schweiz) AGas of 31 Dec 2021463.50k0.85%
TOBAM SASas of 31 Dec 2020172.46k0.32%
Z�rcher Kantonalbank (Investment Management)as of 31 Dec 2020139.48k0.26%
UBS Asset Management Switzerland AGas of 05 Jan 2022125.50k0.23%
Pictet Asset Management SAas of 31 Aug 202152.61k0.10%
BlackRock Asset Management Schweiz AGas of 06 Jan 202244.87k0.08%
CATAM Asset Management AGas of 30 Nov 202125.76k0.05%
Lombard Odier Asset Management (Switzerland) SAas of 30 Sep 202124.03k0.04%
DWS CH AGas of 30 Nov 20204.00k0.01%
More ▼
Data from 30 Sep 2021 - 31 Dec 2021Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.